[

gilead sciences inc

]

Latest from gilead sciences inc

'From anywhere in world': US firm to supply 1 mn black fungus drug to India

  • American biopharmaceutical firm Gilead Sciences is working on accelerating the supply of Liposomal Amphotericin B injections (AmBisome) to India, used to treat Mucormycosis or Black Fungus
The Union government has been trying to ramp up domestic production of Amphotericin B by rewarding license to 5 pharmaceutical manufacturers to produce this drug as black fungus cases rise. (PTI Photo)(PTI)
The Union government has been trying to ramp up domestic production of Amphotericin B by rewarding license to 5 pharmaceutical manufacturers to produce this drug as black fungus cases rise. (PTI Photo)(PTI)
Updated on May 27, 2021 12:46 PM IST
Copy Link
By | Edited by Ayshee Bhaduri, Hindustan Times, New Delhi

Gilead questions WHO study that cast doubts on drug’s Covid-19 benefits

The American company told Reuters the data appeared inconsistent, the findings were premature and that other studies had validated the drug’s benefits.
The WHO trial was conducted in 11,266 adult patients in more than 30 countries. The evidence was conclusive, the WHO said.(Reuters)
The WHO trial was conducted in 11,266 adult patients in more than 30 countries. The evidence was conclusive, the WHO said.(Reuters)
Published on Oct 16, 2020 02:35 PM IST
Copy Link
Reuters | ByReuters| Posted by Susmita Pakrasi

Remdesivir, hydroxychloroquine did not cut hospital stay or mortality in Covid-19 patients: WHO

The study found the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with Covid-19, the WHO said on Thursday.
A bottle containing the drug Remdesivir is shown by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary on Thursday.(AP Photo)
A bottle containing the drug Remdesivir is shown by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary on Thursday.(AP Photo)
Updated on Oct 16, 2020 08:47 AM IST
Copy Link
Reuters | ByReuters | Posted by Kanishka Sarkar

Mylan to launch generic version of Covid-19 treatment drug remdesivir in India this month

The Drug Controller General of India (DCGI) approved Mylan’s remdesivir version, to be called Desrem, for the treatment of suspected or laboratory confirmed severe incidences of Covid-19 in adults and children, the company said in a statement.
Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial. On Friday, it got conditional approval from the European Commission for use in severe Covid-19 patients.(REUTERS File Photo)
Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial. On Friday, it got conditional approval from the European Commission for use in severe Covid-19 patients.(REUTERS File Photo)
Updated on Jul 06, 2020 05:04 PM IST
Copy Link
Bengaluru | ByReuters | Posted by Anubha Rohatgi

India’s Hetero prices generic remdesivir for Covid-19 treatment at Rs5,400 per vial

India has approved the generic versions made by Cipla and Hetero for restricted emergency use in severe Covid-19 cases.
An ampule of Ebola drug Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany as the spread of coronavirus disease (Covid-19) continues.(Reuters File Photo)
An ampule of Ebola drug Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany as the spread of coronavirus disease (Covid-19) continues.(Reuters File Photo)
Updated on Jun 25, 2020 01:11 PM IST
Copy Link
Bengaluru | ByReuters | Posted by Kanishka Sarkar

Zydus Cadila inks licensing pact with Gilead for remdesivir

Remdesivir, the investigational drug from Gilead Sciences Inc, has been issued an ‘emergency use authorisation’ (EUA) by the United States Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of coronavirus, Zydus Cadila said in a statement.
Two ampules of Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany(REUTERS)
Two ampules of Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany(REUTERS)
Updated on Jun 12, 2020 09:28 PM IST
Copy Link
New Delhi | ByPress Trust of India

Gilead’s remdesivir slows progression of Covid-19 in monkeys: Study

In the study, macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs, according to the study authors.
Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, U.S.(Reuters)
Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, U.S.(Reuters)
Updated on Jun 09, 2020 03:43 PM IST
Copy Link
Reuters | ByReuters| Posted by Susmita Pakrasi

Centre relaxes norms for import of certain drugs

In the draft gazette notification issued on June 5, the health ministry amended the New Drugs and Clinical Trials Rules, 2019, in consultation with the Drugs Technical Advisory Board, which advises the government on all drug-related matters.
The official said the condition related to phase-III the clinical trial is to have the safety and efficacy data in place, which is important to know when you are giving an experimental drug to a patient.(Bloomberg)
The official said the condition related to phase-III the clinical trial is to have the safety and efficacy data in place, which is important to know when you are giving an experimental drug to a patient.(Bloomberg)
Updated on Jun 08, 2020 12:17 AM IST
Copy Link
Hindustan Times, New Delhi | By

Maharashtra banks on Remdesivir drug to fight Covid-19, will buy 10K vials

Gilead Sciences Inc claimed this week that the third phase of Remdesivir’s clinical trial in hospitalised patients with moderate Covid-19 pneumonia showed that a five-day treatment course of the drug resulted in greater clinical improvement as compared to standard care alone.
The Drug Controller General of India VG Somani has approved the use of Gilead Sciences Inc’s Remdesivir drug to treat Covid-19 patients.(Reuters file photo)
The Drug Controller General of India VG Somani has approved the use of Gilead Sciences Inc’s Remdesivir drug to treat Covid-19 patients.(Reuters file photo)
Updated on Jun 06, 2020 10:09 PM IST
Copy Link
Hindustan Times, New Delhi | ByHT Correspondent| Edited by Sabir Hussain

Covid-19: India allows emergency use of remdesivir

Lav Aggarwal said further details on the protocols for use of the intravenous drug will be provided by the government in due course.
Gilead’s remdesivir was earlier under trial for Ebola, but the drug could not pass clinical trials.(REUTERS)
Gilead’s remdesivir was earlier under trial for Ebola, but the drug could not pass clinical trials.(REUTERS)
Updated on Jun 03, 2020 09:28 AM IST
Copy Link
Livemint, New Delhi | ByLeroy Leo

Gilead’s Remdesivir drug mainly helped healthier Covid-19 patients: Report

The drug helped patients infected with the novel coronavirus heal faster, allowing them to return home after about 11 days, compared to 15 days for those who were treated with a placebo, according to the report in the New England Journal of Medicine.
Gilead said the publication supports the use of remdesivir in the patients studied and noted that the largest benefit was seen in those who didn’t need mechanical ventilation.(Reuters file photo)
Gilead said the publication supports the use of remdesivir in the patients studied and noted that the largest benefit was seen in those who didn’t need mechanical ventilation.(Reuters file photo)
Updated on May 23, 2020 08:15 AM IST
Copy Link
ByBloomberg| Posted by: Harshit Sabarwal
SHARE
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, January 18, 2022